Chapter 1.
INTRODUCTION: NEUROLOGICAL DISORDERS HAVE CLEAR UNMET NEEDS
1.1. Clarifying the Problems
1.2. Translating the Research

Chapter 2.
CURRENT STATUS AND TRENDS IN TECHNOLOGY TRANSFER
2.1. The Nature of Technology Transfer Today
2.2. Effects of Government Policy on Technology Transfer
Dry-eye Therapeutic Agent
Blood Glucose Monitoring
2.3. Problems Surrounding Technology Transfer
2.4. Translational Medicine Comes to Academia

Chapter 3.
BACKGROUND INFORMATION ON DISEASES TARGETED FOR THIS REPORT
3.1. Alzheimer’s Disease
Key Findings Translated into Therapeutic Advances
State of the Art in Drug Therapy
3.2. Parkinson’s Disease
Key Findings Translated into Therapeutic Advances
State of the Art in Drug Therapy
3.3. Unipolar Depression
Key Findings Translated into Therapeutic Advances
State of the Art in Commercial Applications
3.4. Bipolar Disorder
Key Findings Translated into Therapeutic Advances
State of the Art in Drug Therapy
3.5. Schizophrenia
Key Findings Translated into Therapeutic Advances
State of the Art in Drug Therapy

Chapter 4.
CURRENT BASIC RESEARCH FINDINGS WITH HIGH POTENTIAL
FOR COMMERCIAL APPLICATIONS
4.1. Alzheimer’s Disease
Compounds and Targets Currently in Discovery or Development
Disease-Modification Approaches
Acetylcholine Receptor Modulation
Other Approaches
Miscellaneous Mechanisms
Recent Advances Potentially Leading to New Therapies
p25/Cdk5
GSK-3
Fyn
ERK Pathway
Wnt Pathway
LR11
Amyloid and Ion Channels
Aß Degrading Enzymes
Oxidative Stress
Microtubule-Associated Proteins
Prostaglandin E2 E Prostanoid Subtype 2 (PGE2 EP2) Receptors
Cholesterol Metabolism and the LDL Receptor
Cannabinoid Receptors
4.2. Parkinson’s Disease
Compounds and Targets Currently in Discovery or Development
Recepter Agonists and Antagonists
Gene Therapy
Other Approaches
Recent Advances Potentially Leading to New Therapies
Leucine-Rich Repeat Kinase 2 (Lrrk2)
Parkin
PINK1
PPARγ
p53
Heme Oxygenase-1
Nicotinic Acetylcholine Receptors (nAChRs)
NADPH Oxidase
4.3. Unipolar Depression
Compounds and Targets in Discovery or Development
Neurotransmitter Modulation
Recent Advances Potentially Leading to New Therapies
Microtubule Stabilization
Cannabinoid CB1 Receptor
The Fibroblast Growth Factor (FGF) System
p11 (S100A10)
PAR-4
PSD-95
Galanin
4.4 Bipolar Disorder
Compounds and Targets in Discovery or Development
Recent Advances Potentially Leading to New Therapies
PSD-95
PACAP
FAT Gene
Protein Kinase C (PKC)
BAG-1
GSK-3
Inositol Metabolism
Arachidonic Acid Cascade
4.5. Schizophrenia
Compounds and Targets in Discovery or Development
Serotonin Receptor Antagonists
Multiple Factors in Causation
Recent Advances Potentially Leading to New Therapies
COMT and PRODH
Protein Kinase C (PKC)
Neuregulin 1
DISC1
Dysbindin-1
PSD-95

Chapter 5.
COMMERCIAL POTENTIAL OF SELECTED RESEARCH FINDINGS
5.1. Alzheimer’s Disease
p25/cdk5
Glycogen synthase kinase-3 (GSK-3)
Fyn
ERK Pathway
Wnt Pathway
LR11 (SorLA)
Amyloid Ion Channels
Aß Degrading Enzymes
Inflammation and Microglia
Oxidative Stress
Microtubule-Associated Proteins
Prostaglandin E2 E Prostanoid Subtype 2 Receptors (PGE2EP2)
Cholesterol Metabolism and the LDL Receptor
Cannabinoid Receptors
Summary
5.2. Parkinson’s Disease
Lrrk2
Parkin
PINK1
PPARγ
p53
Heme Oxygenase-1 (HO-1)
Nicotinic Acetylcholine Receptors (nAChRs)
NADPH Oxidase
Summary
5.3. Unipolar Depression
Microtubule Stabilization
Cannabinoid CB1 Receptor
The Fibroblast Growth Factor (FGF) System
p11 (S100A10)
PAR-4
PSD-95
Galanin
Summary
5.4. Bipolar Disorder
PSD-95
PACAP
FAT Gene
Protein Kinase C (PKC)
BAG-1
GSK-3
Inositol Metabolism
Arachidonic Acid Cascade
Summary
5.5. Schizophrenia
COMT and PRODH
Protein Kinase C (PKC)
Neuregulin
DISC1
Dysbindin-1
PSD-95
Summary

Chapter 6.
EXPERT COMMENTARIES
6.1. Mark A. Smith, PhD, Professor of Pathology, Case Western Reserve University
6.2. Maryka Quik, PhD, Professor, The Parkinson’s Institute
6.3. Ross L. Stein, PhD, Director, Laboratory for Drug Discovery in Neurodegeneration, Harvard Center for Neurodegeneration and Repair
6.4. Susan L. Stoddard, PhD, Licensing Manager, Mayo Clinic
6.5. Michael Palfreyman, PhD, DSc, Vice President, Program Management and Drug Development, En Vivo Pharmaceuticals
6.6. C. Anthony Altar, Ph.D., President and CSO, Psychiatric Genomics
6.7. Robert G. Urban, PhD, President and CEO, Acretia
6.8. Pamela Sklar, MD, PhD, Associate Professor of Psychiatry, Harvard Medical School

Chapter 7.
COMPANY PROFILES
7.1. Acadia Pharmaceuticals
7.2. Axonyx
7.3. Biomind
7.4. Cortex
7.5. Cytos Biotechnology
7.6. Elan
7.7. En Vivo
7.8. ExonHit
7.9. GlaxoSmithKline
7.10. Lay Line Genomics
7.11. Memory Pharmaceuticals
7.12. Merck & Co.
7.13. Neuro3D
7.14. Neurochem
7.15 Nymox
7.16. Panacea Pharmaceuticals
7.17. Psychiatric Genomics
7.18. Roche
7.19. sanofi-aventis
7.20. TorreyPines Therapeutics

References

Index